mecasermin rinfabate
Preclinical
Novo Nordiskmecasermin rinfabate is one of 45 therapeutic programs targeting Growth. It is currently in Preclinical.
1
Indications
0
Total Trials
0
Active Trials
44
Competitors
Pipeline
Status by Indication[1]
Competition
Competitive Landscape
79 competitors in Growth
#DrugCompanyPhaseTrials
1Growth Hormone
PfizerPhase 3
Neo-Synephrine
EExela Pharma Sciences, LLC.
Phase 3
Recombinant Human Growth Hormone
Changchun GeneScience Pharmaceutical Co., Ltd.Phase 3
Piqray
NovartisPhase 2
Acipimox
Boehringer IngelheimPhase 2
Lenvima
EisaiPreclinical
Zolymbus
AbbViePreclinical
Zyloprim
Jazz PharmaceuticalsPreclinical
Aricept
EisaiPreclinical
TY-9591
TTYK Medicines, Inc
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Sources
References
- [1]Open Targets Platform — Drug–disease associations for mecasermin rinfabate. EMBL-EBI & Wellcome Sanger Institute.
- [2]
Details
Drug Info
Quick Facts
- Highest Phase
- Preclinical
- Company